Filing Details

Accession Number:
0000950170-24-088544
Form Type:
4
Zero Holdings:
No
Publication Time:
2024-07-31 16:05:07
Reporting Period:
2024-07-29
Accepted Time:
2024-07-31 16:05:07
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1607678 Viking Therapeutics Inc. VKTX Pharmaceutical Preparations (2834) 461073877
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1614578 Brian Lian C/O Viking Therapeutics, Inc.
9920 Pacific Heights Blvd, Suite 350
San Diego CA 92121
President & Ceo No No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock, Par Value $0.00001 Per Share Acquisiton 2024-07-29 41,000 $0.00 2,307,453 No 4 A Direct
Common Stock, Par Value $0.00001 Per Share Acquisiton 2024-07-29 163,333 $0.00 2,470,786 No 4 A Direct
Common Stock, Par Value $0.00001 Per Share Disposition 2024-07-30 65,941 $56.95 2,404,845 No 4 S Direct
Common Stock, Par Value $0.00001 Per Share Disposition 2024-07-30 19,501 $57.81 2,385,344 No 4 S Direct
Common Stock, Par Value $0.00001 Per Share Disposition 2024-07-30 30,417 $58.78 2,354,927 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 A Direct
No 4 A Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
Footnotes
  1. The reported securities were subject to a performance restricted stock unit award that was granted on January 4, 2021, 33.33% of which vested on July 29, 2024 upon the achievement of a non-financial performance goal.
  2. The reported securities were subject to a performance restricted stock unit award that was granted on January 3, 2024, 33.33% of which vested on July 29, 2024 upon the achievement of a non-financial performance goal.
  3. These shares were automatically sold on a non-discretionary basis soley to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of certain shares of common stock subject to certain performance restricted stock unit awards.
  4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $56.46 to $57.45, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
  5. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $57.46 to $58.45, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
  6. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $58.46 to $59.00, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.